NCT Number: NCT01131832
Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols
The substantial range of individual responsiveness to plant sterols has important ramifications. Marked differences across individuals in particular aspects of the cholesterol metabolic pathway must alter the impact of plant sterol consumption. As such, a pronounced need exists to understand the genetic and metabolic factors that explain the substantial degree of heterogeneity in response of lipid concentrations to plant sterols across individuals. The primary focus of this trial is to delineate the impact of differing cholesterol synthesis levels on response of LDL-C and other plasma lipids to plant sterol consumption. Participants pre-identified as high or low endogenous cholesterol synthesizers, according to their screening level of lathosterol to cholesterol ratios, will be given PS or a placebo containing margarine to consume under supervision for 4 weeks in a crossover design. The trial will characterize the responsiveness of the participants' total, LDL, and HDL cholesterol, as well as triacylglycerol (TG) concentrations, to plant sterol consumption. This research will determine if cholesterol synthesis phenotype predicts the responsiveness of lipids to plant sterol consumption. Variations in candidate genes involved in cholesterol metabolism will also be investigated in order to find associations with both cholesterol metabolism phenotypes and responsiveness of lipids to plant sterols. The output of this research will be to advance the knowledge of which genetic factors influence the degree of cardiovascular benefit derived from plant sterols through lipid lowering.
Looking for future studies?
Notify MeKey information
Conditions
Age range
30 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba, Winnipeg, Manitoba, Canada
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- fasting serum LDL cholesterol >3.0 mmol/L
- high or low lathosterol to cholesterol ratio
Exclusion criteria
- smoking
- use of lipid lowering therapy
- documented cardiovascular/atherosclerotic disease
- inflammatory disease
- diabetes
- uncontrolled hypertension
- kidney disease
- liver disease
- other systemic diseases
- cancer
- chronic alcohol consumption (> 2 servings/day)
Treatment and study plan
Placebo
Dietary SupplementPrimary outcomes
-
Serum Lipids
Time frame: Baseline (Day 1,2) and Endpoint (Day 27,28) of each experimental period
Total Cholesterol, LDL-C, HDL-C, Triglycerides
-
Serum non-cholesterol sterols
Time frame: Baseline (Day 1,2) and Endpoint (Day 27,28) of each experimental period
Lathosterol,Lanosterol,Desmosterol,Sitosterol,Campesterol,Cholestanol,
-
Genotype via single nucleotide polymorphism analysis
Time frame: Baseline
SNP genotyping in genes related to cholesterol metabolism
Secondary outcomes
-
Cholesterol synthesis measurement by deuterium incorporation
Time frame: Endpoint (Day 27,28) of each experimental period
Cholesterol biosynthesis will be determined as the rate of incorporation of deuterium from body water into red blood cell membrane free cholesterol over a 24 hour period (day 27 to day 28 of each period). The change in deuterium enrichment within red blood cell free cholesterol will be determined as an index of synthesis, the fractional synthesis rate (FSR) of cholesterol.
-
Change in cholesterol absorption due to plant sterol consumption
Time frame: Change in cholesterol absorption from control period (measured over days 24-28) to plant sterol period (days 24-28)
Ninety-six hours before the end of each period, participants will ingest 65 mg [3, 4-13C]-cholesterol. The 13C-cholesterol will be dissolved in 5 g of warmed margarine, and consumed on a slice of bread. A fasted blood sample will be taken at baseline on day 24 prior to isotope administration, as well as fasting samples on days 25, 26, 27 and 28 to monitor enrichment levels of 13C-cholesterol in plasma total cholesterol. The area under the curve of 13C-cholesterol from 0-96 hours (days 24-28) at the end of the control period will be compared to the same area under the curve at the end of the plant sterol period to determine the change in cholesterol absorption due to plant sterol consumption.
Sponsors and collaborators
Lead sponsor
University of Manitoba
Other
Registry information
Important dates
- Study start
- 2010
- Primary completion
- 2012
- Study completion
- 2012
- First posted
- May 27, 2010
- Registry last updated
- May 9, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Amelioration of Lipid Profile Through Date Cider-vinegar Along With 5:2 Intermittent Fasting
NCT07710898
Diabete Mellitus, Diabetes Mellitus
Lahore, Pakistan
View Trial DetailsEffect of the β-sitosterol-enriched Dietary Plan on Lipid Levels.
NCT07696559
Dyslipidemias, Hyperlipidemia
Lahore, Pakistan
View Trial DetailsLipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
NCT00001154
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemia
Bethesda, Maryland, United States
View Trial DetailsTelephone Based Management of Hyperlipidemia
NCT01212159
Dyslipidemias, Hyperlipidemia
Philadelphia, Pennsylvania, United States
View Trial Details